NGS 546 Gene Oncomine Comprehensive Assay Plus

The Oncomine Comprehensive Assay Plus is a targeted, next-generation sequencing (NGS) assay that provides a comprehensive genomic profiling solution appropriate for formalin-fixed paraffin-embedded (FFPE) tissues. The assay allows concurrent analysis of DNA and RNA to simultaneously detect multiple biomarkers associated with targeted and immune checkpoint research, including comprehensive targets relevant to cancer, in a single workflow. The Oncomine Comprehensive Assay Plus covers over 500 unique genes, including key cancer driver genes such as EGFR, BRAF, KRAS, ERBB2, and MET, fusions involving ALK, ROS1, RET, and NTRK1/2/3, and more.

Key highlights of the Oncomine Comprehensive Assay Plus

• Profile 500+ unique genes for single-gene and multiple-gene biomarker insights
• Detect single gene biomarkers from all variant types including SNVs, indels, CNVs, known and novel fusions, and splice variants
• Analyze complex multi-gene biomarkers for mutational signatures, including tumor mutational burden (TMB) microsatellite instability (MSI) for immunotherapy research
• Detect deficiencies in homology recombination repair (HRR) by assessing variants in 42 HRR pathway genes and genomic instability with sample-level loss of heterozygosity (LOH)
• Detect complex loss of function variants (including gene-level LOH) in key HRR genes, including BRCA1 and BRCA2. Clinical Indications: Cover all the Solid Tumors ( Lung, Breast, Ovarian, Prostate, Thyroid, Melanoma, Thymus, Uterine, Glioma, Gastrointestinal Stromal Tumor, Bladder, Pancreatic, Hepatocellular Carcinomas, Sarcomas.)

Note: Genetic counseling can be provided. If interested, please send the request to this email id: [email protected]

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.